Chiron's Conservative Cash Play
Executive SummaryTwo years after selling off its diagnostics business, Chiron has finally decided how to spend some of the money: it bought Pathogenesis for about $700 million. The move brings one small marketed product, and complementary research capacity that promises mostly longer-term benefit for Chiron's interests in infectious diseases. Analysts and investors aren't thrilled by the conservative move, but they're not bailing out either.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.